In the last 30 days there have been a couple of shares in particular on the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) which have stood out with strong gains.

March was very kind to the shareholders of these two shares, but will April prove to be just as kind, or could things be about to take a turn for the worse?

The two shares are as follows:

Fairfax Media Limited (ASX: FXJ)

In the last month the share price of Fairfax Media has climbed by a huge 13% off its 52-week low, regaining a large portion of its declines so far in 2016.

Things do appear to be picking up for Fairfax Media. It was reported on Thursday in the Sydney Morning Herald that Fairfax publications had reached 11 million people through its sites and apps in February.

If the company can maintain this strong performance then there is a good chance that we may see a boost to its advertising revenue in its full year results.

Despite this, I wouldn’t expect a repeat performance of last month in April. The shares were on the cheap side a month ago, whereas now they look about fair value at 13 times estimated FY2016 earnings.

McMillan Shakespeare Limited (ASX: MMS)

The shares of McMillan Shakespeare are up over 10% in the last month on the back of news that it has been appointed as a vehicle leasing partner for the New South Wales government.

This appointment meant the salary packaging and vehicle leasing administration company became one of six companies able to compete for the financing of 22,000 government-owned vehicles.

Similar to Fairfax Media, its shares had been down close to 52-week lows prior to the announcement. This rally has taken the shares well and truly off those lows now, but still some distance from its 52-week highs.

However, I wouldn’t expect any significant moves higher from the shares for now. There is the threat of the federal budget being brought forward and an early double dissolution election.

There are concerns over the future of salary packaging and fringe benefits tax. A new budget could bring about regulatory changes which negatively impacts the company’s business model. Until the budget is out of the way, I would expect subdued buying of McMillan Shakespeare’s shares.

Foolish takeaway

Both shares performed fantastically well in March, but I’m a little sceptical over their prospects in April after climbing high so quickly. I would be more inclined to look at a share like Ramsay Health Care Limited (ASX: RHC) or the share mentioned below.

BRAND NEW! Our Top Dividend Stock for 2016

Our resident dividend expert names his Top Dividend Share for 2016. Not only are the shares dirt cheap, the company is trading on a 5.6% fully franked dividend yield. Simply click here to gain access to this comprehensive FREE investment report, including the name of this fast growing ASX dividend share. No credit card required!

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.